Chest
CorrespondenceRisk Factors for Isoniazid Hepatotoxicity in Children With Latent TB and TB: Difference From Adults
Section snippets
To the Editor
Isoniazid (INH) is still the mainstay of the treatment of both active and latent TB. The main adverse effect of this worldwide-used drug was hepatotoxicity, which had a wide spectrum, changing from mild transient elevations1 in aminotransferases to severe hepatitis leading to liver transplantation.2 The incidence of INH hepatotoxicity was reported to range from 0.1 at the low end to from 4% to 8% at the high end in different studies. The studies concerning childhood TB and INH hepatotoxicity in
References (0)
Cited by (15)
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies
2016, EBioMedicineCitation Excerpt :There has been reluctance to perform dose–response studies and first in human studies in children because of concerns for toxicity such as drug induced liver injury (DILI). Indeed, the incidence of DILI among children treated for TB ranges between 1.7–8%, making this a legitimate concern (Devrim et al., 2010; Roy et al., 2006) Recently, the World Health Organization and STOP-TB have advocated for the design of new and shorter treatment regimens for children, leading to zero TB deaths in children. Thus the problem is pressing.
Hepatotoxicity of antitubercular drugs
2013, Drug-Induced Liver DiseaseIsoniazid toxicity in a 5-year-old boy
2013, CMAJ. Canadian Medical Association JournalCitation Excerpt :Several risk factors for liver toxicity have been identified, including HIV infection, daily alcohol consumption, age over 34 years, pregnancy and the postpartum period (within 3 mo of delivery), concomitant use of other hepatotoxic drugs and underlying liver disease.4,8 The incidence of toxicity increases with age,8 although age has not been found to affect the incidence of isoniazid hepatotoxicity in studies involving pediatric patients.9 Slow acetylation of isoniazid due to genetic polymorphisms in the gene encoding N-acetyltransferase 2 and polymorphisms of cytochrome P450 2E1 that result in increased activity of the enzyme have both been associated with raised levels of transaminases during therapy.
Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis
2023, Gastroenterology and Hepatology from Bed to BenchAn updated review on isoniazid-induced hepatotoxicity and it's influencing factors
2022, Chinese Journal of New DrugsIsoniazid-induced hepatotoxicity in children with latent tuberculosis infection
2021, Minerva Pediatrics
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestpubs.org/site/misc/reprints.xhtml).